SCHEMBL2250944

SCHEMBL2250944

NN1CCCC1c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.60
CHRNB4 P30926 1/20 0.60
CHRNA3 P32297 1/20 0.60
CHRNA7 P36544 1/20 0.60
CHRNA4 P43681 1/20 0.60
RIPK1 Q13546 2/20 0.51
NUDT1 P36639 2/20 0.43
RECQL P46063 1/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2251648 0.94 CHRNB2 (0.53) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Hydrochloric Acid SCHEMBL8551847 0.92 CHRNB2 (0.52) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Hydrochloric Acid SCHEMBL9273017 0.92 CHRNB2 (0.52) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL19276478 0.81 CHRNB2 (0.41) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL21599158 0.79 RECQL (0.42) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL19582849 0.78 CHRNA7 (0.67) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL20703257 0.78 RIPK1 (0.58) RIPK1
SCHEMBL19586493 0.78 CHRNA7 (0.67) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL20959170 0.78 RIPK1 (0.58) RIPK1
SCHEMBL23339668 0.75 CHRNB2 (0.60) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026100487-A1 UNDERFILL MATERIAL, CURED PRODUCT, SEMICONDUCTOR PACKAGE, AND METHOD FOR MANUFACTURING SAME 旭化成株式会社 2026-05-15 WO disclosed
WO-2026100491-A1 EPOXY RESIN COMPOSITION, CURED OBJECT, UNDERFILL MATERIAL, ADHESIVE, AND SEMICONDUCTOR PACKAGE AND PRODUCTION METHOD THEREFOR 旭化成株式会社 2026-05-15 WO disclosed
CN-115803323-B Amine imide compound, amine imide composition, curing agent, epoxy resin composition, process for producing amine imide compound, sealing material, and adhesive 旭化成株式会社 2025-05-16 CN disclosed
WO-2025028598-A1 CURING AGENT FOR EPOXY RESINS, EPOXY RESIN COMPOSITION, CURED OBJECT, SEALING MATERIAL, AND ADHESIVE 旭化成株式会社 2025-02-06 WO disclosed
WO-2025028605-A1 CURING AGENT, EPOXY RESIN COMPOSITION, CURED OBJECT, SEALING MATERIAL, AND ADHESIVE 旭化成株式会社 2025-02-06 WO disclosed
WO-2025028611-A1 CURING AGENT FOR EPOXY RESINS, EPOXY RESIN COMPOSITION, CURED OBJECT, SEALING MATERIAL, AND ADHESIVE 旭化成株式会社 2025-02-06 WO disclosed
US-20250034319-A1 EPOXY RESIN COMPOSITION, CURED PRODUCT, ENCAPSULANT AND ADHESIVE ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-01-30 US disclosed
CN-118302470-A Epoxy resin composition, cured product, sealing material, and adhesive 旭化成株式会社 2024-07-05 CN disclosed
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-10-12 US disclosed
WO-2023127800-A1 EPOXY RESIN COMPOSITION, CURED PRODUCT, SEALING MATERIAL, AND ADHESIVE 旭化成株式会社 2023-07-06 WO disclosed
EP-2235007-B1 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2012-10-31 EP disclosed
CN-101910240-B Latent curing agent, epoxy resin composition containing same, sealing agent, and organic EL display MITSUI CHEMICALS INC 2012-10-03 CN disclosed
US-7994164-B2 Mineralocorticoid receptor antagonists and methods of use ELI LILLY AND COMPANY (US) 2011-08-09 US disclosed
CN-101910240-A Latent curing agent, epoxy resin composition containing same, sealing agent, and organic EL display MITSUI CHEMICALS INC 2010-12-08 CN disclosed
CN-101903377-A 6H-dibenzo [ b, e ] oxepane-derived non-steroidal mineralocorticoid receptor antagonists LILLY CO ELI 2010-12-01 CN disclosed
US-20100253213-A1 LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONTAINING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS MITSUI CHEMICALS, INC (JP) 2010-10-07 US disclosed
EP-2235007-A1 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2010-10-06 EP disclosed
EP-2199313-A1 LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONATING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS Mitsui Chemicals, Inc. (JP) 2010-06-23 EP disclosed
WO-2009085584-A1 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2009-07-09 WO disclosed
US-20090163472-A1 MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE ELI LILLY AND COMPANY 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS AZI2, IAPP, ZFX CHRNB2 1245/4885CHRNB4 1598/4885CHRNA3 445/4885
US-20100253213-A1 LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONTAINING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS LTA4H, EPHX2, EPHX1 CHRNB2 3021/4885CHRNB4 2700/4885CHRNA3 3277/4885
US-20090163472-A1 MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE NR3C2, MC2R, REN CHRNB2 2422/4885CHRNB4 2489/4885CHRNA3 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.